DFINE is committed to building scientific evidence to support the use of our products in interventional oncology and broaden adoption of targeted RF ablation in the treatment of painful debilitating spinal metastatic disease. The STAR™ Tumor Ablation System, received FDA 510(k) clearance in 2010. After completing a STAR prospective multicenter clinical series, DFINE is now conducting two prospective clinical studies, one in the United States and one in Europe. A large STAR prospective registry is also being initiated this year to ensure prospective data collection from large numbers of patients benefiting from DFINE technology.
Moving forward the company continues to invest in clinical studies to further improve the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies.
DFINE® sponsors ongoing clinical studies in the United States and Europe:
- Prospective Clinical Series (PCS) | USA
- STARRT Study | USA
- EU STAR | Europe
- STAR Prospective Registry | USA